We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$143M
Turnover
43.75%
1-Year Est. Return
773.18%
This Fund
S&P 500
This Quarter
Est. Return
+42.28%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$142M
AUM Growth
-$5.53M
(-3.8%)
Cap. Flow
-$27M
Cap. Flow
% of AUM
-19.05%
Top 10 Holdings %
Top 10 Hldgs %
77.36%
Holding
36
New
6
Increased
6
Reduced
13
Closed
9
Avg Time Held Equity + Options
1
year
Top 10 Avg Time Held Equity + Options
0.5
years
Top 20 Avg Time Held Equity + Options
0.9
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Erasca
ERAS
|
+$4.19M |
| 2 |
Sutro Biopharma
STRO
|
+$3.65M |
| 3 |
Bright Minds Biosciences
DRUG
|
+$2.22M |
| 4 |
Tango Therapeutics
TNGX
|
+$2.21M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
+$2.19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cidara Therapeutics
CDTX
|
+$19.7M |
| 2 |
Terns Pharmaceuticals
TERN
|
+$5.8M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$4.93M |
| 4 |
Insmed
INSM
|
+$4.5M |
| 5 |
Ocular Therapeutix
OCUL
|
+$4.39M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.59% |
| 2 | Miscellaneous | 2.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Praxis Precision Medicines
PRAX
$6.9B
| $27.4M | 19.3% |
84,901
+1,865
| +2% | +$577K |
2023 Q2
11 quarters
|
|
|
2
DELISTED
Terns Pharmaceuticals
TERN
| $26.1M | 18.44% |
495,772
-141,323
| -22% | -$5.8M |
2022 Q3
14 quarters
|
|
3
Whitehawk Therapeutics
WHWK
$172M
| $11.8M | 8.3% |
3,410,402
| – | – |
2021 Q3
18 quarters
|
|
|
4
Tango Therapeutics
TNGX
$3.75B
| $9.24M | 6.52% |
441,831
+159,099
| +56% | +$2.21M |
2025 Q4
1 quarter
|
|
|
5
Bright Minds Biosciences
DRUG
$527M
| $8.17M | 5.77% |
111,996
+27,519
| +33% | +$2.22M |
2024 Q4
5 quarters
|
|
|
6
Sutro Biopharma
STRO
$189M
| $6.71M | 4.73% |
269,425
+201,974
| +299% | +$3.65M |
2025 Q4
1 quarter
|
|
|
7
Erasca
ERAS
$5.3B
| $5.74M | 4.05% |
+354,575
| New | +$4.19M |
2026 Q1
0 quarters
|
|
8
Surrozen
SRZN
$293M
| $5.04M | 3.55% |
172,847
-5,568
| -3% | -$133K |
2025 Q1
4 quarters
|
|
|
9
Ocular Therapeutix
OCUL
$1.59B
| $5.02M | 3.54% |
592,108
-460,887
| -44% | -$4.39M |
2023 Q4
9 quarters
|
|
10
Compass Therapeutics
CMPX
$158M
| $4.49M | 3.17% |
849,076
-244,224
| -22% | -$1.41M |
2025 Q3
2 quarters
|
|
11
Minerva Neurosciences
NERV
$111M
| $4.27M | 3.02% |
709,500
| – | – |
2025 Q4
1 quarter
|
|
|
12
MoonLake Immunotherapeutics
MLTX
$881M
| $3.57M | 2.52% |
191,760
+132,480
| +223% | +$2.19M |
2025 Q4
1 quarter
|
|
13
argenx
ARGX
$53.6B
| $3.42M | 2.42% |
4,690
-161
| -3% | -$126K |
2024 Q2
7 quarters
|
|
14
Oculis Holding
OCS
$457M
| $2.61M | 1.84% |
98,339
-3,438
| -3% | -$91K |
2025 Q1
4 quarters
|
|
15
Revolution Medicines
RVMD
$40.8B
| $2.54M | 1.79% |
26,069
+17,658
| +210% | +$1.78M |
2023 Q4
9 quarters
|
|
16
Amylyx Pharmaceuticals
AMLX
$3.49B
| $2.1M | 1.48% |
151,067
-182,191
| -55% | -$2.56M |
2025 Q3
2 quarters
|
|
17
Taysha Gene Therapies
TSHA
$1.21B
| $1.96M | 1.39% |
439,464
-15,363
| -3% | -$71.4K |
2025 Q2
3 quarters
|
|
18
IDEAYA Biosciences
IDYA
$3.25B
| $1.61M | 1.13% |
+48,234
| New | +$1.62M |
2026 Q1
0 quarters
|
|
19
Design Therapeutics
DSGN
$649M
| $1.55M | 1.1% |
145,900
-5,006
| -3% | -$50.7K |
2025 Q4
1 quarter
|
|
20
United Therapeutics
UTHR
$23.5B
| $1.32M | 0.93% |
2,224
-72
| -3% | -$35.9K |
2025 Q3
2 quarters
|
|
|
21
CALL
IDEAYA Biosciences
IDYA
$3.25B
| $1.17M | 0.82% |
+350
| New | +$11.7K |
2026 Q1
0 quarters
|
|
22
Entrada Therapeutics
TRDA
$190M
| $1.13M | 0.8% |
+89,358
| New | +$1.02M |
2026 Q1
0 quarters
|
|
23
Avalo Therapeutics
AVTX
$649M
| $908K | 0.64% |
+60,808
| New | +$951K |
2026 Q1
0 quarters
|
|
24
LB Pharmaceuticals
LBRX
$1.19B
| $713K | 0.5% |
28,919
-1,081
| -4% | -$24.9K |
2025 Q3
2 quarters
|
|
25
Maze Therapeutics
MAZE
$1.52B
| $577K | 0.41% |
19,335
-665
| -3% | -$29.3K |
2025 Q4
1 quarter
|
|
Similar funds
FPC
WWM
AVA
BOM
PWM
FF
JPT
BJF
Acuta Capital Partners's Q1 2026 Portfolio in Review
As of Q1 2026, Acuta Capital Partners held 36 positions worth $142M, down 3.8% from $147M the previous quarter. Its ten largest holdings account for 77% of the portfolio.
Acuta Capital Partners withdrew a net $27M in Q1 2026, closing 9 positions and reducing 13 holdings. Its most notable exit was Cidara Therapeutics, an estimated $19.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Acuta Capital Partners opened a new position in Erasca worth $5.74M.
- Acuta Capital Partners's largest Q1 2026 buy was Erasca: 354,575 shares worth $5.74M.
- Acuta Capital Partners added most to Sutro Biopharma in Q1 2026, an estimated $3.65M increase.
- Acuta Capital Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $5.8M.
- Acuta Capital Partners fully exited Cidara Therapeutics in Q1 2026, selling an estimated $19.7M.
- Acuta Capital Partners's ten largest holdings make up 77% of its $142M portfolio in Q1 2026.
- Acuta Capital Partners opened 6 new positions and closed 9 in Q1 2026.
- Acuta Capital Partners's portfolio value fell 3.8% quarter-over-quarter to $142M.
Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.